Edition:
United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

56.51USD
24 Nov 2017
Change (% chg)

$0.70 (+1.25%)
Prev Close
$55.81
Open
$55.84
Day's High
$57.61
Day's Low
$54.87
Volume
75,775
Avg. Vol
214,017
52-wk High
$57.67
52-wk Low
$10.31

Chart for

About

Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the... (more)

Overall

Beta: 2.60
Market Cap(Mil.): $1,451.92
Shares Outstanding(Mil.): 25.69
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.97 15.54
EPS (TTM): -- -- --
ROI: -- -10.87 11.80
ROE: -- -36.85 15.75

BRIEF-Esperion Therapeutics Q3 loss per share $1.86‍​

* Esperion provides bempedoic acid franchise development program updates; reports third quarter 2017 financial results

Nov 07 2017

BRIEF-Esperion announces initiation of pivotal late stage study for bempedoic acid

* Esperion announces initiation of pivotal late stage study for the bempedoic acid / ezetimibe combination pill

Nov 06 2017

BRIEF-Esperion Therapeutics - Phase 3 results for bempedoic acid expected in Q2, Q3 2018

* Esperion Therapeutics- bempedoic acid top-line results from studies 1, 3 and 4 are expected in Q2 2018, results from study 2 expected in Q3 2018

Oct 02 2017

BRIEF-Meditor Group Ltd reports 8.2 pct passive stake in Esperion Therapeutics Inc

* Meditor Group Ltd reports 8.2 percent passive stake in Esperion Therapeutics Inc as on Aug 10 - SEC filing​ Source text (http://bit.ly/2x6jGbc) Further company coverage:

Aug 21 2017

BRIEF-Esperion announces proposed public offering of common stock

* Esperion announces proposed public offering of common stock

Aug 08 2017

BRIEF-Co announces positive top-line results from Phase 2 study of Bempedoic Acid / Ezetimibe combination plus Atorvastatin​

* Says Esperion announces positive top-line results from Phase 2 study of Bempedoic Acid / Ezetimibe combination plus Atorvastatin​

Aug 08 2017

BRIEF-Esperion reports initiation of phase 2 study of bempedoic acid added-on to a pcsk9 inhibitor

* Esperion announces initiation of phase 2 study of bempedoic acid added-on to a pcsk9 inhibitor

Jul 26 2017

Earnings vs. Estimates